Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.

A treatment for alopecia areata could move forward despite a setback in a midstage clinical trial.

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Dr. Hordinsky discusses how clascoterone 5% topical solution may reshape male AGA management and expand treatment confidence.

Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...

MELANIE Sykes has revealed she’s been left “two-thirds bald” and in “so much pain” after being diagnosed with alopecia. The autoimmune disease causes varying levels ...

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...

A Las Vegas woman who was crowned Miss Nevada in July made history at the Miss USA pageant by becoming the first contestant ...